Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Axogen Inc (AXGN) vs Caesars Entertainment Inc (CZR) Price & Performance

Axogen IncTrade
Caesars Entertainment IncTrade

Price performance (Past 24H)

Key statistics

Axogen Inc vs Caesars Entertainment Inc — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Caesars Entertainment Inc trades at $29.63 (market cap $6.06B). The key difference: Caesars Entertainment Inc is far larger — about 2.3× Axogen Inc's market cap. Which is the better fit depends on your goals.

AXGNCZR
Market Cap
$2.61B$6.06B
Sector
TechnologyConsumer Cyclical
52-Week High
$48.48$30.41
52-Week Low
$14.16$18.14
Enterprise Value
$2.52B$29.95B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Axogen Inc

AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.

Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.

Caesars Entertainment Inc

Caesars Entertainment (CZR) trades at $29.62, down 1.5% on the day, with a bearish technical signal and recent quarterly earnings misses. The company reported a Q2 2026 loss of $0.30 per share, missing estimates, but revenue of $3.0 billion topped expectations. Fundamentals show a negative net income margin of -3.99% and high long-term debt of $12.03 billion, though operating cash flow remains strong at $1.30 billion in 2025. The pending acquisition by Tilman Fertitta for approximately $17.6 billion is a key development, as reported by the Wall Street Journal on July 28, 2026.

CZR presents a mixed outlook with acquisition potential offset by persistent losses and debt. The stock's low P/S ratio of 0.52 offers value, but investors face risks from earnings volatility and competitive pressures in the leisure sector. Analyst sentiment is cautious with 70% hold ratings, reflecting uncertainty around profitability improvements and integration post-acquisition.

Returns comparison

Trailing returns across standard periods

About Axogen Inc

Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.

Read more on AXGN

About Caesars Entertainment Inc

Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.

Read more on CZR